Most of the Bispecific T-cell Engagers (BiTEs) under development for treatment of DLBCL engage the CD3 invariant subunit of the T-cell receptor complex and CD19 (CD19 x CD3 BiTE) or CD20 (CD20 xCD3 BiTE) on lymphoma cells (33, 55). The gene discussed is CD19; the disease is lymphoma.